Quinoline derivatives and pharmaceutical compositions and methods for

Abstract

The invention is concerned with novel quinicine and cinchonicine derivatives having cardiovascular activities of the formula or a salt thereof, ##STR1## in which A--B is --CH.sub.2 --CH.sub.2, --CHOH--CH.sub.2 --, --CH.sub.2 --CHOH--, --C(O)--CH.sub.2 --, --CH.sub.2 --C(O)--, --C(NOR.sup.4)--CH.sub.2 -- or --CH.sub.2 --C(NOR.sup.4)--; R.sup.1 is hydrogen, hydroxy or lower alkoxy; R.sup.2 is ethyl or vinyl; R.sup.3 is C.sub.2-8 alkyl, C.sub.1-8 hydroxyalkyl, lower alkoxy-alkyl or lower alkanoyloxyalkyl, C.sub.3-6 cycloalkyl, hydroxycycloalkyl, lower alkoxycycloalkyl or lower alkanoyloxycycloalkyl, cycloalkyl lower alkyl, hydroxy-, lower alkoxy- or lower alkanoyloxycycloalkyl lower alkyl; cyano, cyano lower alkyl, lower alkenyl, lower alkynyl, tetrahydrofuryl, mono- or di-lower alkylamino lower alkyl, mono- or di-lower alkylamino lower hydroxy alkyl; optionally substituted phenyl, phenyl lower alkyl or phenyl hydroxy lower alkyl, optionally substituted diphenyl lower alkyl, optionally substituted phenyl lower alkenyl, optionally substituted benzoyl or benzoyl lower alkyl, optionally substituted heteroaryl or heteroaryl lower alkyl, or optionally substituted heteroaroyl or heteroaroyl lower alkyl; R.sup.4 is lower alkyl, and Z is hydrogen, lower alkyl or optionally substituted phenyl, or Z and R.sup.3 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group, whereby the substituents at the 3- and 4-position of the piperidine ring are in the cis-position, excluding N-[C.sub.2-6 alkyl, C.sub.2-6 hydroxyalkyl, NN-di-lower alkylamino lower alkyl, optionally substituted C.sub.7-11 aralkyl] substituted derivatives of quinicine and cinchonicine. The compounds of the formula may be in the form of their optically active enantiomers and/or their therapeutically acceptable salts. Methods for the preparation of the compounds of the formula are also disclosed and form part of the invention.